Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis
Menée sur un modèle murin, cette étude montre que le gène Ptpn11, qui code pour la tyrosine phosphatase Shp2, joue un rôle suppresseur de tumeurs dans le développement d'un carcinome hépatocellulaire
The human gene Ptpn11, which encodes the tyrosine phosphatase Shp2, may act as a proto-oncogene because dominantly activating mutations have been detected in several types of leukemia. Herein we report a tumor-suppressor function of Shp2. Hepatocyte-specific deletion of Shp2 promotes inflammatory signaling through the Stat3 pathway and hepatic inflammation/necrosis, resulting in regenerative hyperplasia and development of tumors in aged mice. Furthermore, Shp2 ablation dramatically enhanced diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) development, which was abolished by concurrent deletion of Shp2 and Stat3 in hepatocytes. Decreased Shp2 expression was detected in a subfraction of human HCC specimens. Thus, in contrast to the leukemogenic effect of dominant-active mutants, Ptpn11/Shp2 has a tumor-suppressor function in liver. º Hepatic deletion of Ptpn11 promotes hepatocarcinogenesis º Detection of deficient/low Shp2 expression in human HCC specimens º Ptpn11/Shp2 may act as either tumor promoter or suppressor º Stat3 has both pro-oncogenic and anti-oncogenic effects in HCC
Cancer Cell 2011